Our top pick for
Rosetta Stone Inc is a software-application business based in the US. Rosetta Stone shares (RST) are listed on the NYSE and all prices are listed in US Dollars. Rosetta Stone employs 746 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$0.00 - $0.00|
|50-day moving average||$29.95|
|200-day moving average||$23.52|
|Wall St. target price||$30.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.62|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Rosetta Stone stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Rosetta Stone's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Rosetta Stone's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.9 million.
The EBITDA is a measure of a Rosetta Stone's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$188.5 million|
|Gross profit TTM||$145.4 million|
|Return on assets TTM||-5.9%|
|Return on equity TTM||0%|
|Market capitalisation||$738 million|
TTM: trailing 12 months
There are currently 611,785 Rosetta Stone shares held short by investors – that's known as Rosetta Stone's "short interest". This figure is 46.2% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting Rosetta Stone shares can be evaluated.
Rosetta Stone's "short interest ratio" (SIR) is the quantity of Rosetta Stone shares currently shorted divided by the average quantity of Rosetta Stone shares traded daily (recently around 1.9 million). Rosetta Stone's SIR currently stands at 0.32. In other words for every 100,000 Rosetta Stone shares traded daily on the market, roughly 320 shares are currently held short.
However Rosetta Stone's short interest can also be evaluated against the total number of Rosetta Stone shares, or, against the total number of tradable Rosetta Stone shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rosetta Stone's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Rosetta Stone shares in existence, roughly 20 shares are currently held short) or 0.0263% of the tradable shares (for every 100,000 tradable Rosetta Stone shares, roughly 26 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Rosetta Stone.
Find out more about how you can short Rosetta Stone stock.
We're not expecting Rosetta Stone to pay a dividend over the next 12 months.
Rosetta Stone's shares were split on a 1:4 basis on 4 November 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rosetta Stone shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Rosetta Stone shares which in turn could have impacted Rosetta Stone's share price.
Over the last 12 months, Rosetta Stone's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Rosetta Stone's is 0.7711. This would suggest that Rosetta Stone's shares are less volatile than average (for this exchange).
Rosetta Stone Inc. , together with its subsidiaries, provides technology-based learning products in the United States and internationally. It operates through three segments: Literacy, E&E Language, and Consumer Language. The company develops, markets, and supports a suite of language-learning and literacy solutions consisting of web-based software subscriptions, online and professional services, and mobile applications, as well as practice applications. It also provides administrative tools for performance monitoring, and measure and track learner progress; professional services; and custom solutions, including curriculum development, global collaboration programs, group and live tutoring, and language courses for mission-critical government programs. The company offers its products under the Rosetta Stone, The Blue Stone Logo, Lexia, Lexia PowerUP Literacy, and TruAccent trademarks. It sells its products and services through call centers, websites, app-stores, third party e-commerce websites, retail resellers, consignment distributors, daily deal partners, home shopping resellers, and third-party resellers and distributors, as well as directly to individuals, educational institutions, corporations, and government agencies.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.